Latest Hotspot

SELLAS announces promising initial results from the SLS009 Phase 1 lymphoma group study, advancing to Phase 2 clinical trial

30 September 2023
3 min read

SELLAS Life Sciences Group, Inc., an advanced clinical stage biopharmaceutical firm concentrating on innovating new treatment options for various forms of cancer, today shared promising preliminary results from the segment of patients with recurrent or unresponsive lymphoma in the Phase 1 dosage-enhancement study of its CDK9 inhibitor, SLS009 (GFH009).

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

All primary and secondary research aims, including those related to safety, clinical efficiency, pharmacokinetics, and pharmacodynamics, have been successfully achieved. The suggested Phase 2 dosage for lymphoma patients has been identified at the highest assessed level of 100 mg, provided as a once-weekly infusion. 

The ceiling tolerated dosage was not met. One out of five patients treated with a 100 mg dosage had a dose-limiting toxicity. There were no dose-limiting toxic events at any other dosage levels, and the study was not marred by any unexpected toxicity. 

"We are thrilled to reveal impactful preliminary results from the Phase 1 trial of SLS009 for lymphoma patients, reinforcing the encouraging results in acute myeloid leukemia patients that we announced earlier this year," stated Angelos Stergiou, MD, ScD h.c., the President and Chief Executive Officer of SELLAS.

Stergiou went on to say, "The data proves significant anti-cancer activity and clinical responses when used as standalone therapy. Given its positive therapeutic profile, SLS009 is increasingly being acknowledged as a possible treatment for individuals suffering from hematologic cancers who have already gone through all available treatment routes. Our ally, GenFleet Therapeutics, is planning to propel GFH009 (SLS009) into Phase 2 clinical research in China for patients with peripheral T-cell lymphoma later this year."

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

According to the data provided by the Synapse Database, As of September 28, 2023, there are 52 investigational drugs for the CDK9 target, including 87 indications,71 R&D institutions involved, with related clinical trials reaching 173and as many as 2685 patents.

The aim of creating GFH-009 is to establish a viable therapy alternative for individuals afflicted with diverse forms of cancers and pathologies related to the urogenital, hemic, and lymphatic systems. The medicinal drug intends to disrupt the aberrant cellular proliferation and division procedures associated with these illnesses by focusing on CDK9.

图形用户界面, 文本, 应用程序

描述已自动生成

Krystal Biotech reports FDA approval of the investigational new drug application for KB408 to treat Type 1 Alpha-1 Antitrypsin Deficiency
Latest Hotspot
3 min read
Krystal Biotech reports FDA approval of the investigational new drug application for KB408 to treat Type 1 Alpha-1 Antitrypsin Deficiency
30 September 2023
Krystal Biotech publicized that the U.S. FDA has given the green light for the Investigational New Drug application for KB408 to manage alpha-1 antitrypsin deficiency.
Read →
Analysis on the Clinical Research Progress of PDL1 inhibitors
Analysis on the Clinical Research Progress of PDL1 inhibitors
30 September 2023
Programmed death-ligand 1 (PD-L1) is a protein found on the surface of certain cells in the human body, including immune cells and some cancer cells.
Read →
The European Commission has approved Jazz Pharmaceuticals' Enrylaze® for Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma treatment
Latest Hotspot
3 min read
The European Commission has approved Jazz Pharmaceuticals' Enrylaze® for Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma treatment
30 September 2023
Jazz Pharmaceuticals plc has proclaimed that the EC has approved the commercialization of Enrylaze®(JZP458; a derivative of Erwinia asparaginase or crisantaspase).
Read →
Cardiovascular Disease Treatment Drug - PDE3 Inhibitors
Cardiovascular Disease Treatment Drug - PDE3 Inhibitors
30 September 2023
PDE3 has the ability to hydrolyze both cAMP and cGMP, but its ability to hydrolyze cAMP is about ten times that of cGMP.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.